<SEC-DOCUMENT>0001078782-21-000428.txt : 20210511
<SEC-HEADER>0001078782-21-000428.hdr.sgml : 20210511
<ACCEPTANCE-DATETIME>20210511161241
ACCESSION NUMBER:		0001078782-21-000428
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20210511
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210511
DATE AS OF CHANGE:		20210511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VOLITIONRX LTD
		CENTRAL INDEX KEY:			0000093314
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				911949078
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36833
		FILM NUMBER:		21911433

	BUSINESS ADDRESS:	
		STREET 1:		13215 BEE CAVE PARKWAY
		STREET 2:		GALLERIA OAKS B, SUITE 125
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78738
		BUSINESS PHONE:		1 (646) 650-1351

	MAIL ADDRESS:	
		STREET 1:		13215 BEE CAVE PARKWAY
		STREET 2:		GALLERIA OAKS B, SUITE 125
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78738

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STANDARD CAPITAL CORP
		DATE OF NAME CHANGE:	19990812
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k051121_8k.htm
<DESCRIPTION>FORM 8-K CURRENT REPORT
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXAC8S3T1P2VFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE>Form 8-K Current Report</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:36pt;width:540pt><P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>UNITED STATES</B></P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>Washington, D.C. 20549</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>FORM 8-K</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>CURRENT REPORT</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>PURSUANT TO SECTION 13 OR 15(d) OF </B><BR><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>Date of Report (Date of earliest event reported): &nbsp;<B>May 11, 2021</B></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=center style='font:16pt Times New Roman;margin:0;color:#000000'><B>VolitionRx Limited</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'> (Exact name of registrant as specified in its charter)</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<TABLE align=center style=border-collapse:collapse><TR><TD valign=middle style=width:151.5pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style=width:162.75pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style=width:147.75pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:151.5pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'><B>Delaware</B></P>
</TD><TD valign=top style=width:162.75pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'><B>001-36833</B></P>
</TD><TD valign=top style=width:147.75pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'><B>91-1949078</B></P>
</TD></TR>
<TR><TD valign=top style=width:151.5pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(State or other jurisdiction </P>
</TD><TD valign=top style=width:162.75pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(Commission File Number)</P>
</TD><TD valign=top style=width:147.75pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(IRS Employer </P>
</TD></TR>
<TR><TD valign=top style=width:151.5pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>of Incorporation) </P>
</TD><TD valign=top style=width:162.75pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:147.75pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>Identification Number) </P>
</TD></TR>
<TR><TD valign=top style=width:151.5pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:162.75pt;padding:0.75pt><P align=center style='font:12pt Times New Roman;margin:0'><BR><FONT style=font-size:10pt><B>13215 Bee Cave Parkway</B></FONT></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Suite 125, Galleria Oaks B</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Austin, Texas 78738</B></P>
</TD><TD valign=top style=width:147.75pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD></TR>
<TR><TD colspan=3 valign=top style=width:462pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(Address of principal executive offices and Zip Code)</P>
<P align=center style='font:10pt Times New Roman;margin:0'> &nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:151.5pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:162.75pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'><B>+1 (646) 650-1351</B></P>
</TD><TD valign=top style=width:147.75pt;padding:0.75pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD></TR>
<TR><TD colspan=3 valign=top style=width:462pt;padding:0.75pt><P align=center style='font:10pt Times New Roman;margin:0'>(Registrant&#8217;s telephone number, including area code)&#160;</P>
</TD></TR>
</TABLE>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>Not applicable</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>(Former name or former address, if changed since last report) </P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#000000'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>[ &nbsp;&nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>[ &nbsp;&nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>[ &nbsp;&nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>[ &nbsp;&nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Securities registered pursuant to Section 12(b) of the Act:</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:5.65pt'>&#160;</P>
<TABLE align=center style=border-collapse:collapse;width:90.84%><TR><TD valign=top style='width:25.32%;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Title of Each Class</P>
</TD><TD valign=top style=width:1.1%;padding-bottom:1.5pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style='width:27.52%;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Trading Symbol(s)</P>
</TD><TD valign=top style=width:1.1%;padding-bottom:1.5pt><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style='width:44.96%;border-bottom:1.5pt solid #000000'><P align=center style='font:10pt Times New Roman;margin:0'>Name of Each Exchange on which Registered</P>
</TD></TR>
<TR><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>Common Stock,</P>
<P align=center style='font:10pt Times New Roman;margin:0'>par value $0.001 per share</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top><P align=center style='font:10pt Times New Roman;margin:0'>VNRX</P>
</TD><TD valign=top><P style='font:10pt Times New Roman;margin:0'>&#160;</P>
</TD><TD valign=top style=width:44.96%><P align=center style='font:10pt Times New Roman;margin:0'>NYSE American, LLC</P>
</TD></TR>
</TABLE>
<P style='font:10pt Times New Roman;margin:0;margin-right:16.75pt;color:#211D1E'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#211D1E'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P>
<P align=right style='font:10pt Times New Roman;margin:0;color:#211D1E'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company <FONT style=color:#000000>[ &nbsp;&nbsp;]</FONT></P>
<P style='font:10pt Times New Roman;margin:0;margin-right:36pt;color:#211D1E'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#000000'><FONT style=color:#211D1E>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</FONT> [ &nbsp;&nbsp;]</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>VOLITIONRX LIMITED</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Form 8-K</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Current Report</B></P>
<P style='font:13pt Times;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><B>Item&#160;2.02.</B></KBD><KBD style=margin-left:72pt></KBD><B>Results of Operations and Financial Condition.</B>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>The following information, including Exhibit 99.1, is being &#8220;furnished&#8221; in accordance with General Instruction B.2. of Form&#160;8-K and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>On May 11, 2021, VolitionRx Limited (the &#8220;Company&#8221;) issued a press release announcing its financial results and certain business updates for the quarter ended March 31, 2021. &nbsp;The Company also confirmed its conference call to be held on May&#160;12, 2021 at 8:00 a.m. U.S. Eastern Time. &nbsp;Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:0pt'><B>Item 9.01.</B></KBD><KBD style=margin-left:72pt></KBD><B>Financial Statements and Exhibits.</B>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style='position:absolute;font:10pt Times New Roman;margin-left:36pt'>(d) </KBD><KBD style='position:absolute;font:10pt Times New Roman;margin-left:72pt'>Exhibits.</KBD><KBD style=margin-left:108pt></KBD> &nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:478.8pt><TR><TD valign=top style=width:68.4pt><P style='font:10pt Times New Roman;margin:0'>Exhibit</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Number</FONT></P>
</TD><TD valign=top style=width:410.4pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Description</FONT></P>
</TD></TR>
<TR style=height:13.5pt><TD valign=top style=width:68.4pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=f8k051121_ex99z1.htm style=text-decoration:none>99.1</A></FONT></P>
</TD><TD valign=top style=width:410.4pt><P style='font:12pt Times New Roman;margin:0'><FONT style=font-size:10pt>Press Release of VolitionRx Limited, dated May 11, 2021.</FONT></P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'><B>SIGNATURE</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt;color:#000000'>Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:97.04%><TR style=height:7.2pt><TD valign=top style=width:51.5%><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD colspan=2 valign=middle style=width:48.5%><P style='font:10pt Times New Roman;margin:0;text-indent:-13.95pt;margin-left:13.95pt'><B>VOLITIONRX LIMITED</B></P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-13.95pt;margin-left:13.95pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;text-indent:-13.95pt;margin-left:13.95pt'>&nbsp;</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=middle style=width:51.5%;padding-bottom:1.2pt><P style='font:10pt Times New Roman;margin:0'>Date: May 11, 2021 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
</TD><TD valign=top style=width:4.3%;padding-bottom:1.2pt><P style='font:10pt Times New Roman;margin:0'>By: </P>
</TD><TD valign=middle style=width:44.2%><P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>/s/ Cameron Reynolds &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=middle style=width:51.5%;padding-bottom:1.2pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:4.3%;padding-bottom:1.2pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style=width:44.2%><P style='font:10pt Times New Roman;margin:0'>Cameron Reynolds</P>
</TD></TR>
<TR style=height:7.2pt><TD valign=middle style=width:51.5%;padding-bottom:1.2pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:4.3%;padding-bottom:1.2pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=middle style=width:44.2%><P style='font:10pt Times New Roman;margin:0'>Chief Executive Officer &amp; President</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>EXHIBIT INDEX</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;width:549pt><TR><TD valign=top style=width:54pt><P style='font:10pt Times New Roman;margin:0'><B>Exhibit</B></P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>Number</B></FONT></P>
</TD><TD valign=top style=width:495pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><B>Description</B></FONT></P>
</TD></TR>
<TR style=height:7.2pt><TD valign=top style=width:54pt><P style='font:10pt Times New Roman;margin:0'><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><A href=f8k051121_ex99z1.htm style=text-decoration:none>99.1</A></FONT></P>
</TD><TD valign=top style=width:495pt><P style='font:10pt Times New Roman;margin:0'> Press Release of VolitionRx Limited, dated May 11, 2021.</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k051121_ex99z1.htm
<DESCRIPTION>EXHIBIT 99.1 PRESS RELEASE OF VOLITIONRX LIMITED, DATED MAY 11, 2021.
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2021 [PPXAC8S3T1P2VFDLV1AJ]. www.edgarsuite.com -->
<HEAD>
<TITLE>Exhibit 99.1 Press Release of VolitionRx Limited, dated May 11, 2021.</TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:36pt;width:523.3pt><P align=center style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:11pt Times New Roman;margin:0'><A name=_Hlk66457689 /><B>VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update</B></P>
<P style='font:10pt Times New Roman;margin:0;margin-left:54pt'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-left:36pt'><A name=_DV_M2 /><B>Conference call to discuss financial and operational results scheduled for</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-left:36pt'><A name=_DV_M3 /><B>Wednesday, May 12, at 8:00 a.m. U.S. Eastern Time</B></P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-left:36pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'><KBD style='position:absolute;font:10pt Symbol;margin-left:0pt'>&#183;</KBD><KBD style=margin-left:18pt></KBD>Secured strongest-ever balance sheet with approximately $33.1 million in cash&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'><KBD style='position:absolute;font:10pt Symbol;margin-left:0pt'>&#183;</KBD><KBD style=margin-left:18pt></KBD>Strengthened the Company&#8217;s leadership team to drive commercial focus&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'><KBD style='position:absolute;font:10pt Symbol;margin-left:0pt'>&#183;</KBD><KBD style=margin-left:18pt></KBD>Expanded the Company&#8217;s intellectual property portfolio &nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'><KBD style='position:absolute;font:10pt Symbol;margin-left:0pt'>&#183;</KBD><KBD style=margin-left:18pt></KBD>Initiated production of product components at scale at the Company&#8217;s Silver One facility&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'><KBD style='position:absolute;font:10pt Symbol;margin-left:0pt'>&#183;</KBD><KBD style=margin-left:18pt></KBD>Published three clinical papers&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'><KBD style='position:absolute;font:10pt Symbol;margin-left:0pt'>&#183;</KBD><KBD style=margin-left:18pt></KBD>Continued focus on product launches and licensing in both the human and veterinary spaces<BR>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt;color:#000000'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>AUSTIN, Texas, May 11, 2021 /PRNewswire/</B> -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;) today announced financial results and a business update for the first quarter ended March 31, 2021. Volition management will host a conference call tomorrow, May 12 at 8:00 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><A name=_DV_M5 />&#8220;We have made significant progress on many fronts during 2021 on all four of the Company&#8217;s key pillars: Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT>, Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet, Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> NETs and Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Capture,&#8221; commented Cameron Reynolds, President and Chief Executive Officer of Volition. &#8220;We have also significantly strengthened our balance sheet, our intellectual property portfolio, and our executive team to drive commercial focus.&#8221;  </P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>An interview with Cameron Reynolds, President and Chief Executive Officer and Terig Hughes, Chief Financial Officer.</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>https://youtu.be/un7YtAecF7o</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Mr. Reynolds continued, &#8220;Silver One, our manufacturing facility and service lab, is proving to have been an excellent addition to Volition&#8217;s commercialization efforts and is now producing finished product and components at commercial scale for our anticipated product launches. I am delighted that the Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet beta launch has not only provided revenue but also invaluable real-world learnings allowing us to move ahead soon with our expected national U.S. and international launches. We are also seeing a high level of interest in both the licensing and distribution of our products and are actively negotiating multiple agreements.&#8221; </P>
<P align=justify style='font:10pt Times New Roman;margin:0'><A name=_DV_M7 /><A name=_DV_M8 /><A name=_DV_M10 /><A name=_DV_M13 /><A name=_DV_M14 /><A name=_DV_M16 /><A name=_DV_M17 /><A name=_DV_M20 /><A name=_DV_M22 /><BR><B>Company Highlights</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'><BR><FONT style='border-bottom:1px solid #000000'><I>Financial</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Cash and cash equivalents as of March 31, 2021 totaled approximately $33.1 million compared with $19.4&#160;million as of December 31, 2020.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>During the first quarter of 2021, added an aggregate of approximately $20.3 million in cash mostly through an underwritten public offering of our common stock that closed in February, as well as through periodic sales of common stock under Volition&#8217;s at-the-market equity distribution program.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Secured a further $4 million in non-dilutive funding consisting of a cash grant of $1.3 million and loans totalling $2.7&#160;million from the Walloon Regional Government and associated agencies.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Continued to manage expenditures carefully with a cash burn rate of approximately $2 million per month.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Personnel</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>As Volition transitions from a research and development company to a commercial company, it strengthened the leadership team with the appointment of a new Chief Financial Officer, Mr. Terig Hughes, as well as the appointment of Mr.&#160;Gael Forterre as Chief Commercial Officer. &nbsp;In addition, Volition promoted Dr. Gaetan Michel to Chief Operating Officer and Dr.&#160;Mark Eccleston to Chief Technology Officer.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition announced the appointment of two Independent Directors to its main Board &#8211;&nbsp;Kim Nguyen, an HR executive with global expertise at Google, and Richard Brudnick, a pharmaceutical business executive with extensive commercial know-how.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>As of May 1, Dr. Tom Butera, a seasoned veterinary executive with an extensive commercial track record, joined the team as Chief Executive Officer of Volition&#8217;s Veterinary subsidiary to drive its product launches.&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Intellectual Property</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>28 patent families covering both human and animal use of Volition&#8217;s Nucleosomics&#8482; platform.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>64 granted patents (ten in the U.S., 14 in Europe and 42 rest of world).&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>93 patents pending.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Continued focus on filings during the first quarter and expect portfolio to grow in the quarters and years ahead.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Publications</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition&#8217;s list of publications and abstracts is growing.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Year to date data for Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> has been presented at two international conferences and Volition has collaborated on three clinical paper publications.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>These publications are another very important step forward for the Company.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Nu.Q</I><I><SUP>&#174;</SUP></I><I> </I><I>Vet Cancer Screening Test Beta Launch</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Beta launch of the Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet Cancer Screening Test in late November 2020 in Texas. This beta launch is facilitating real-world learnings to help shape the marketing mix before Volition&#8217;s planned launch nationally across the U.S. expected in the next few months.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition has received strong indications of interest in the whole Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet platform, from a range of small and very large companies, and it is progressing potential licensing discussions with several well-known major players in the veterinary space around the world.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>In addition to the Texas beta launch, Volition is finalizing beta launch planning in both Asia and Europe.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Nu.Q</I><I><SUP>&#174;</SUP></I><I> </I><I>Capture</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>The clinical paper published in Nature&#8217;s Scientific Reports in March highlighted for the first time that histone H2A1R3 citrulline is, in plasma, upregulated in colorectal cancer patients and so could be a biomarker Volition targets for future Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> immunoassay development. &nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>It showed that the use of Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Capture may open up the possibility of using mass spectrometry not only for biomarker discovery but also as a high throughput platform for screening and/or diagnostics.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition aims for Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Capture to be an important enabling technology in the liquid biopsy space and expects to launch its first product with this technology in 2022.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Clinical &#8211;&nbsp;</I><I>NETosis</I><I> including COVID-</I><I>19</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition believes that the versatility of the Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> platform and the range of applications for which these assays can be leveraged may help increase diagnostic power and monitor disease progression and potentially treatment response across a broad range of diseases that involve the over production of NETs, such as COVID-19, pneumonia, influenza and sepsis.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>From a sepsis product development perspective, to date Volition has completed animal studies in the monitoring of disease progress and treatment efficacy which have demonstrated the effective use of Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> NETs.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Human studies in the monitoring of disease progress and treatment efficacy in sepsis are now underway at a leading UK hospital.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>From a COVID-19 product development perspective, Volition has conducted studies of serial testing of COVID-19 patients at leading UK hospitals to determine the predictive value of its test, with further data due to be presented at upcoming conferences and potentially additional studies and collaborations as well. &nbsp;&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'><I>Clinical &#8211;&nbsp;Cancer</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>As previously reported, due to the pandemic collection for the U.S. EDRN study for colorectal cancer has been paused, and collection for the blood cancer studies in the U.S. have been delayed with an updated timeline expected in the near future.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>In Asia, Volition has reached its target patient cohorts for both colorectal cancer studies and the lung cancer study, all collected in conjunction with the National Taiwan University, notwithstanding the pandemic. &nbsp;Volition expects to run the assays and finalize the analysis over the coming months with data due to be reported at future conferences.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition has installed a Service Lab in Silver One, which will undertake sample processing for external parties such as pharmaceutical companies, biotech companies and academic researchers. This service, branded as Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Discover, has already generated interest, and Volition expects to see initial revenue from this during 2021.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition is producing recombinant nucleosomes in-house and at large-scale, building a library for sale through Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Discover and also for internal R&amp;D use.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Volition is still in active discussions on its first potential licensing deal with a large healthcare company.&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><A name=_DV_M23 /><A name=_DV_M46 /><A name=_DV_M51 /><A name=_DV_M52 /><A name=_DV_M53 /><A name=_DV_M54 /><A name=_DV_M55 /><A name=_DV_M56 /><A name=_DV_M57 /><A name=_DV_M58 /><A name=_DV_M59 /><A name=_DV_M60 /><A name=_DV_M61 /><A name=_DV_M63 /><A name=_DV_M65 /><A name=_DV_M66 /><A name=_DV_M69 /><A name=_DV_M70 /><A name=_DV_M76 /><FONT style='border-bottom:1px solid #000000'><I>Upcoming Milestones</I></FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><A name=_DV_M77 />Volition expects to achieve the following milestones during 2021 and beyond, pandemic permitting:</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>National launch of the Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet Cancer Screening Test in the U.S. &nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Beta launches of the Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet Cancer Screening Test in Asia and Europe.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Continue to focus on driving revenue in the coming quarters in four key areas:&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:10pt Courier New;margin-left:-18pt'>&#111;</KBD>Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Vet products, &nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:10pt Courier New;margin-left:-18pt'>&#111;</KBD>Disease monitoring tests (e.g. Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> NETs for COVID-19, sepsis), &nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:10pt Courier New;margin-left:-18pt'>&#111;</KBD>Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Discover, and &nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:54pt'><KBD style='position:absolute;font:10pt Courier New;margin-left:-18pt'>&#111;</KBD>Licensing of its technology for others to commercialize in both humans and animals.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Continue to progress the research program for the use of Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> in NETosis, in monitoring disease progression of COVID-19, sepsis and potentially other diseases and as a possible companion diagnostic for a treatment for sepsis.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Continue to advance its previously announced large-scale blood, lung and colorectal cancer trials in Europe, Asia and the U.S.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Publish several abstracts and peer-reviewed scientific papers with clinical results showing the robustness and utility of its Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> platform.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Advance the development of Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> Capture.&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:18pt'><A name=_DV_M81 /><KBD style='position:absolute;font:10pt Symbol;margin-left:-18pt'>&#183;</KBD>Continue to file patents to expand and extend its intellectual property portfolio.&nbsp;</P>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><A name=_DV_M82 /><A name=_DV_M83 /><A name=_DV_M84 /><A name=_DV_M85 /><A name=_DV_M87 /><A name=_DV_M88 /><A name=_DV_M89 /><A name=_DV_M92 /><A name=_DV_M93 /><A name=_DV_M94 /><A name=_DV_M95 /><A name=_DV_M96 /><A name=_DV_M97 /><A name=_DV_M98 /><A name=_DV_M99 />&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>VolitionRx Limited First Quarter 2021</B></P>
<P align=center style='font:10pt Times New Roman;margin:0'><B>Financial Results and Business Update</B></P>
<P style='font:10pt Times New Roman;margin:0;margin-left:18pt'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:36pt></KBD><B>Date: </B>Wednesday, May 12, 2021&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:36pt></KBD><B>Time: </B>8:00 a.m. U.S. Eastern time&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:36pt></KBD><B>U.S. &amp; Canada Dial-in: </B>1-877-407-9716 (toll free)&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:36pt></KBD><B>U.K. Dial-in: </B>0 800 756 3429 (toll free)&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;text-indent:36pt'><B>Toll/International: </B>1-201-493-6779</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><KBD style=margin-left:36pt></KBD><B>Conference ID: &nbsp;13719633</B>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;margin-left:36pt'><A name=_DV_M100 /><A name=_DV_M101 /><A name=_DV_M102 /><A name=_DV_M103 /><A name=_DV_M104 /><A name=_DV_M105 />&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><A name=_DV_M106 />Cameron Reynolds, President and Chief Executive Officer of Volition, will host the call along with Terig Hughes, Chief Financial Officer and Scott Powell, Executive Vice President, Investor Relations. </P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#000000'>A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at <FONT style='border-bottom:1px solid #000000'>http://ir.volition.com</FONT>. In addition, a telephone replay of the call will be available until May 26, 2021. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13719633.</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#000000'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'><B>About Volition</B></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics&#8482;, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>For more information about Volition, visit Volition's website <FONT style='border-bottom:1px solid #000000'>volition.com</FONT> or connect with us via:</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Twitter: <FONT style='border-bottom:1px solid #000000'>https://twitter.com/volitionrx</FONT> </P>
<P align=justify style='font:10pt Times New Roman;margin:0'>LinkedIn: <FONT style='border-bottom:1px solid #000000'>https://www.linkedin.com/company/volitionrx </FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Facebook: <FONT style='border-bottom:1px solid #000000'>https://www.facebook.com/VolitionRx/ </FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#0000FF'><FONT style=color:#000000>YouTube: </FONT><FONT style='color:#000000;border-bottom:1px solid #000000'>https://www.youtube.com/user/VolitionRx</FONT></P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. &nbsp;The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><B>Media / Investor Contacts</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<TABLE style=border-collapse:collapse;margin-left:-6.05pt><TR style=height:36.9pt><TD valign=bottom style=width:220.35pt><P style='font:10pt Times New Roman;margin:0;margin-left:6pt'><B>Louise Batchelor, Volition</B></P>
<P style='font:10pt Times New Roman;margin:0;margin-left:6pt'><FONT style='border-bottom:1px solid #000000'>mediarelations@volition.com</FONT></P>
<P style='font:10pt Times New Roman;margin:0;margin-left:6pt'><B>+44 (0)7557 774620</B></P>
</TD><TD valign=bottom style=width:188.85pt><P style='font:10pt Times New Roman;margin:0'><B>Scott Powell, Volition</B></P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>investorrelations@volition.com</FONT></P>
<P style='font:10pt Times New Roman;margin:0'><B>+1 (646) 650 1351</B></P>
</TD></TR>
<TR style=height:36pt><TD valign=bottom style=width:220.35pt><P style='font:10pt Times New Roman;margin:0;margin-left:5.25pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0;margin-left:5.25pt'><B>Jen Lewis, Pegasus</B></P>
<P style='font:10pt Times New Roman;margin:0;margin-left:5.25pt;color:#0000FF'><FONT style='color:#000000;border-bottom:1px solid #000000'>jen.lewis@thisispegasus.co.uk</FONT></P>
<P style='font:10pt Times New Roman;margin:0;margin-left:5.25pt'><B>+44 (0)7809 867943</B></P>
</TD><TD valign=top style=width:188.85pt><P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><B>Joseph Green, Edison Advisors</B></P>
<P style='font:10pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>jgreen@edisongroup.com</FONT></P>
<P style='font:10pt Times New Roman;margin:0'><B>+1 (646) 653 7030</B></P>
</TD></TR>
</TABLE>
<HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<P style='font:10pt Times New Roman;margin-top:0pt;margin-bottom:8pt'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:10pt Times New Roman;margin:0'><A name=_DV_M122 /><A name=_DV_M125 /><B>Safe Harbor Statement</B></P>
<P style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>Statements in this press release may be &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;targets,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;optimizing,&#8221; &#8220;potential,&#8221; &#8220;goal,&#8221; &#8220;suggests,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;will&#8221; and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing, completion and delivery of data from clinical studies, the effectiveness of Volition&#8217;s blood-based<A name=_DV_M123 /> diagnostic and prognostic tests, Volition&#8217;s ability to develop and successfully commercialize such test platforms for early detection of cancer<A name=_DV_C132 /> and other diseases as well as serving as a diagnostic or prognostic tool for COVID-19, and the timing of product launches and publications.<A name=_DV_M124 /> Volition&#8217;s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition&#8217;s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition&#8217;s development pipeline or any other diagnostic or prognostic products Volition might develop; Volition&#8217;s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition&#8217;s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition&#8217;s most recent Annual Report on Form&#160;10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition&#8217;s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.</P>
<P align=justify style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=justify style='font:10pt Times New Roman;margin:0;color:#000000'>Nucleosomics&#8482; and Nu.Q<FONT style=font-size:8pt><SUP>&#174;</SUP></FONT> and their respective logos are trademarks and/or service marks of <A name=_DV_C133 />VolitionRx <A name=_DV_M126 />Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to &#8220;$&#8221; refer to the legal currency of the United States of America.</P>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
